Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:27 AM
Ignite Modification Date:
2025-12-25 @ 12:27 AM
NCT ID:
NCT02956967
Eligibility Criteria:
Inclusion Criteria:
* Male and female patients ≥ 18 years
* Declaration of informed consent signed by patient
* Patients with a solid tumour or with a malignant haematological tumour
* Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle
* GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment
* Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN
Exclusion Criteria:
* Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)
* Patients who are hypersensitive to one of the excipients of NivestimTM
* Patients not undergoing chemotherapy
* Patients being treated curatively or as secondary prophylaxis with G-CSF
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02956967
Study Brief:
Protocol Section:
NCT02956967